Posted by Michael Wonder on 08 Jun 2021
BerGenBio receives FDA fast track designation for bemcentinib/anti-PD-(L)1 combination in NSCLC
8 June 2021 - First recognition by a regulator of AXL positive patients as a target population.
BerGenBio today announces that the U.S. FDA has granted fast track designation for bemcentinib in combination with an anti-PD-(L)1 agent for the treatment of patients with AXL positive advanced/metastatic non-small cell lung cancer.
